185 related articles for article (PubMed ID: 25414443)
1. Therapeutic targeting of the BCR-associated protein CD79b in a TCR-based approach is hampered by aberrant expression of CD79b.
Jahn L; Hombrink P; Hassan C; Kester MG; van der Steen DM; Hagedoorn RS; Falkenburg JH; van Veelen PA; Heemskerk MH
Blood; 2015 Feb; 125(6):949-58. PubMed ID: 25414443
[TBL] [Abstract][Full Text] [Related]
2. Generation of CD20-specific TCRs for TCR gene therapy of CD20low B-cell malignancies insusceptible to CD20-targeting antibodies.
Jahn L; van der Steen DM; Hagedoorn RS; Hombrink P; Kester MG; Schoonakker MP; de Ridder D; van Veelen PA; Falkenburg JH; Heemskerk MH
Oncotarget; 2016 Nov; 7(47):77021-77037. PubMed ID: 27776339
[TBL] [Abstract][Full Text] [Related]
3. Chimeric Antigen Receptor T Cells Targeting CD79b Show Efficacy in Lymphoma with or without Cotargeting CD19.
Ormhøj M; Scarfò I; Cabral ML; Bailey SR; Lorrey SJ; Bouffard AA; Castano AP; Larson RC; Riley LS; Schmidts A; Choi BD; Andersen RS; Cédile O; Nyvold CG; Christensen JH; Gjerstorff MF; Ditzel HJ; Weinstock DM; Barington T; Frigault MJ; Maus MV
Clin Cancer Res; 2019 Dec; 25(23):7046-7057. PubMed ID: 31439577
[TBL] [Abstract][Full Text] [Related]
4. A CD22-reactive TCR from the T-cell allorepertoire for the treatment of acute lymphoblastic leukemia by TCR gene transfer.
Jahn L; Hagedoorn RS; van der Steen DM; Hombrink P; Kester MG; Schoonakker MP; de Ridder D; van Veelen PA; Falkenburg JH; Heemskerk MH
Oncotarget; 2016 Nov; 7(44):71536-71547. PubMed ID: 27689397
[TBL] [Abstract][Full Text] [Related]
5. CAR T Cell Therapy in Acute Lymphoblastic Leukemia and Potential for Chronic Lymphocytic Leukemia.
Singh N; Frey NV; Grupp SA; Maude SL
Curr Treat Options Oncol; 2016 Jun; 17(6):28. PubMed ID: 27098534
[TBL] [Abstract][Full Text] [Related]
6. An alternatively spliced form of CD79b gene may account for altered B-cell receptor expression in B-chronic lymphocytic leukemia.
Alfarano A; Indraccolo S; Circosta P; Minuzzo S; Vallario A; Zamarchi R; Fregonese A; Calderazzo F; Faldella A; Aragno M; Camaschella C; Amadori A; Caligaris-Cappio F
Blood; 1999 Apr; 93(7):2327-35. PubMed ID: 10090943
[TBL] [Abstract][Full Text] [Related]
7. T cells raised against allogeneic HLA-A2/CD20 kill primary follicular lymphoma and acute lymphoblastic leukemia cells.
Abrahamsen IW; Kjellevoll S; Greve-Isdahl M; Mensali N; Wälchli S; Kumari S; Loland BF; Egeland T; Kolstad A; Olweus J
Int J Cancer; 2012 Apr; 130(8):1821-32. PubMed ID: 21630262
[TBL] [Abstract][Full Text] [Related]
8. Chimeric antigen receptor T cells to target CD79b in B-cell lymphomas.
Chu F; Cao J; Liu J; Yang H; Davis TJ; Kuang SQ; Cheng X; Zhang Z; Karri S; Vien LT; Bover L; Sun R; Vega F; Green M; Davis RE; Neelapu SS
J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 38007239
[TBL] [Abstract][Full Text] [Related]
9. Autoreactive, cytotoxic T lymphocytes specific for peptides derived from normal B-cell differentiation antigens in healthy individuals and patients with B-cell malignancies.
Grube M; Rezvani K; Wiestner A; Fujiwara H; Sconocchia G; Melenhorst JJ; Hensel N; Marti GE; Kwak LW; Wilson W; Barrett JA
Clin Cancer Res; 2004 Feb; 10(3):1047-56. PubMed ID: 14871984
[TBL] [Abstract][Full Text] [Related]
10. A novel TCR-like CAR with specificity for PR1/HLA-A2 effectively targets myeloid leukemia in vitro when expressed in human adult peripheral blood and cord blood T cells.
Ma Q; Garber HR; Lu S; He H; Tallis E; Ding X; Sergeeva A; Wood MS; Dotti G; Salvado B; Ruisaard K; Clise-Dwyer K; John LS; Rezvani K; Alatrash G; Shpall EJ; Molldrem JJ
Cytotherapy; 2016 Aug; 18(8):985-994. PubMed ID: 27265873
[TBL] [Abstract][Full Text] [Related]
11. The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor.
Hudecek M; Schmitt TM; Baskar S; Lupo-Stanghellini MT; Nishida T; Yamamoto TN; Bleakley M; Turtle CJ; Chang WC; Greisman HA; Wood B; Maloney DG; Jensen MC; Rader C; Riddell SR
Blood; 2010 Nov; 116(22):4532-41. PubMed ID: 20702778
[TBL] [Abstract][Full Text] [Related]
12. Induction of melanoma antigen-specific cytotoxic T lymphocytes in vitro by stimulation with B7-expressing human melanoma cell lines.
Fenton RG; Turcovski-Corrales SM; Taub DD
J Immunother; 1998 Mar; 21(2):95-108. PubMed ID: 9551360
[TBL] [Abstract][Full Text] [Related]
13. Aberrant B cell receptor signaling from B29 (Igbeta, CD79b) gene mutations of chronic lymphocytic leukemia B cells.
Gordon MS; Kato RM; Lansigan F; Thompson AA; Wall R; Rawlings DJ
Proc Natl Acad Sci U S A; 2000 May; 97(10):5504-9. PubMed ID: 10792036
[TBL] [Abstract][Full Text] [Related]
14. TCR-based therapy for multiple myeloma and other B-cell malignancies targeting intracellular transcription factor BOB1.
Jahn L; Hombrink P; Hagedoorn RS; Kester MG; van der Steen DM; Rodriguez T; Pentcheva-Hoang T; de Ru AH; Schoonakker MP; Meeuwsen MH; Griffioen M; van Veelen PA; Falkenburg JH; Heemskerk MH
Blood; 2017 Mar; 129(10):1284-1295. PubMed ID: 28053195
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic targeting of naturally presented myeloperoxidase-derived HLA peptide ligands on myeloid leukemia cells by TCR-transgenic T cells.
Klar R; Schober S; Rami M; Mall S; Merl J; Hauck SM; Ueffing M; Admon A; Slotta-Huspenina J; Schwaiger M; Stevanović S; Oostendorp RA; Busch DH; Peschel C; Krackhardt AM
Leukemia; 2014 Dec; 28(12):2355-66. PubMed ID: 24736212
[TBL] [Abstract][Full Text] [Related]
16. Structural and energetic evidence for highly peptide-specific tumor antigen targeting via allo-MHC restriction.
Simpson AA; Mohammed F; Salim M; Tranter A; Rickinson AB; Stauss HJ; Moss PA; Steven NM; Willcox BE
Proc Natl Acad Sci U S A; 2011 Dec; 108(52):21176-81. PubMed ID: 22160697
[TBL] [Abstract][Full Text] [Related]
17. CAR T-cells merge into the fast lane of cancer care.
Frey NV; Porter DL
Am J Hematol; 2016 Jan; 91(1):146-50. PubMed ID: 26574400
[TBL] [Abstract][Full Text] [Related]
18. In vivo effects of targeting CD79b with antibodies and antibody-drug conjugates.
Zheng B; Fuji RN; Elkins K; Yu SF; Fuh FK; Chuh J; Tan C; Hongo JA; Raab H; Kozak KR; Williams M; McDorman E; Eaton D; Ebens A; Polson AG
Mol Cancer Ther; 2009 Oct; 8(10):2937-46. PubMed ID: 19808977
[TBL] [Abstract][Full Text] [Related]
19. Identification of CD19 and CD20 peptides for induction of antigen-specific CTLs against B-cell malignancies.
Bae J; Martinson JA; Klingemann HG
Clin Cancer Res; 2005 Feb; 11(4):1629-38. PubMed ID: 15746068
[TBL] [Abstract][Full Text] [Related]
20. Efficiency of CD19 chimeric antigen receptor-modified T cells for treatment of B cell malignancies in phase I clinical trials: a meta-analysis.
Zhang T; Cao L; Xie J; Shi N; Zhang Z; Luo Z; Yue D; Zhang Z; Wang L; Han W; Xu Z; Chen H; Zhang Y
Oncotarget; 2015 Oct; 6(32):33961-71. PubMed ID: 26376680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]